Report
Teaser, summary, work performed and final results
Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)
Teaser
Atopic dermatitis (AD) is associated with significant co-morbidity. The solution provided by AntibioTx represents a new mode of action. The objectives of the project are to verify the promise of the drug product and advance commercial understanding to bring the solution to...
Summary
Atopic dermatitis (AD) is associated with significant co-morbidity. The solution provided by AntibioTx represents a new mode of action. The objectives of the project are to verify the promise of the drug product and advance commercial understanding to bring the solution to market.
Work performed
The current stage of development of the proposed solution aligns with a Technology Readiness Level 7 since the drug compound had been tested on human subject volunteers. The project helped to establish the definition development plans for the solution in questions. This includes assessment of regulatory route, interaction with regulatory consultants and competent authorities, as well as clinical study design to bring forward its market authorisation agenda. This process has been developed with clinical advisors and KOLs within dermatology.
Final results
The project is designed to demonstrate how the solution in question can contribute to address the medical need in atopic dermatitis and offer a better treatment due to the new mode of action. Early data provides evidence for the potential to change the treatment paradigm of dermatological diseases by providing an innovative and significantly differentiated treatment.
Website & more info
More info: http://www.antibiotx.com/.